- SB TEMPUS supports more personalised healthcare for each patient by collecting and analysing medical data using AI.
- The establishment of the joint venture will help Japan enhance its position and influence in the global medical market.
OUR TAKE
Tempus is committed to changing the precision medicine landscape through the practical application of AI, and the collaboration with SBG will expand its reach and bring its AI solutions to the Japanese market. They are able to work together because they share a common goal: to ensure that patients benefit from personalised, data-driven treatments that help them live longer, healthier lives.
–Zora Lin, BTW reporter
What happened
SoftBank Group Corporation (SBG) announces a joint venture, “SB TEMPUS Corp.,” with TEMPUS AI, a leader in artificial intelligence and precision medicine, on June 27. The parties will invest 15 billion yen in the joint venture, which aims to provide precision medicine services in Japan, while SB TEMPUS aims to use artificial intelligence to further advance the development of healthcare in Japan. It will draw on Tempus’ accumulated expertise and technology in the United States.
Tempus is connected to approximately 50 percent of oncologists in the United States and has one of the industry’s largest deidentified molecular, clinical and imaging databases. SB TEMPUS plans to leverage the expertise and technology TEMPUS has developed through its operations in the United States to provide precision medicine services in Japan, including genetic testing, medical data collection and analysis, and AI-driven treatment options.
SoftBank Group’s corporate philosophy is “Information Revolution – Happiness for all.” Masayoshi Son, Chairman and CEO of SoftBank Group, says: “We are very pleased to establish a joint venture with Tempus in Japan to contribute to the development of healthcare. I strongly hope that by promoting the development of AI personalized medicine, we can reduce people’s sadness and increase people’s happiness as much as possible.”
Also read: SoftBank uses call centre AI to calm the sound of angry customers
Also read: Tempus AI’s IPO: investor confidence in genomics diagnostics
Why it’s important
SoftBank Group’s partnership with Tempus will drive diagnostics and treatments based on medical data and artificial intelligence. Contributing to significant advances in healthcare through close cooperation with the Japanese medical industry.
The establishment of SB TEMPUS will accelerate the application of AI in the medical field, marking a further acceleration of the application of AI technology in the medical field. By integrating the technologies and resources of both parties, the joint venture will be able to develop more efficient and precise medical solutions to provide patients with more personalised and scientific treatment plans.
SoftBank Group and Tempus AI are from Japan and the United States, respectively, and the healthcare system and technology level of the two countries are different. The establishment of the joint venture will promote the cooperation and exchanges between the two countries in the medical field and promote the common progress and development of medical technology on both sides.
As a well-known technology company in Japan, SoftBank Group’s cooperation with Tempus AI, a leading international medical technology company, will further enhance Japan’s international competitiveness in the medical field. The establishment of the joint venture will help Japan achieve more innovations and breakthroughs in the medical field and enhance its position and influence in the global medical market.
